Spectroscopic Assessment of Tissue Oxygenation Changes During Vascular Surgery

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorSpectrocor

About this trial

This study is a single-center, observational study designed to collect tissue spectrometric data related to tissue oxygenation.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults, age of 18 - 90 years

Scheduled for peripheral arterial bypass surgery.

Scheduled for proximal arterial reconstruction.

Ability and willingness to provide informed consent.

Disqualifiers

Inability to provide informed consent

Considered a vulnerable person according to the Finnish Medical Research Act (488/1999), Chapter 2, Sections 7, 9, and 10, including retarded persons, pregnant women, nursing mothers, prisoners, and forensic patients.

A known history of severe allergic reaction to nickel.

Trial population

A Helsinki University Hospital patient scheduled for a vascular surgical operation.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Observe changes in skeletal muscle tissue oxygenation

To observe the changes in skeletal muscle tissue oxygenation (combined hemoglobin/myoglobin saturation, %) measured by the SpectroCor Monitoring System during arterial clamping and restoration of limb perfusion. Continuous spectroscopic measurement of combined hemoglobin and myoglobin oxygen saturation in skeletal muscle of the operated limb, recorded from a SpectroCor Sensor placed in the distal wound before any arterial clamping. Saturation values are time-stamped against intraoperative events affecting limb perfusion (proximal arterial clamping, unclamping, graft revision) and compared with paired arterial and venous blood gas samples obtained before clamping and after restoration of blood flow.

Time frame
From sensor placement prior to arterial clamping until restoration of limb blood circulation and completion of vascular reconstruction quality control (intraoperative period, approximately 2-6 hours)

Secondary outcomes

1

Incidence of adverse events, adverse device effects, and device deficiencies

Number and proportion of participants experiencing at least one adverse event (AE), adverse device effect (ADE), serious adverse event (SAE), serious adverse device effect (SADE), or unanticipated serious adverse device effect (USADE), and the number of device deficiencies (DD) recorded. Events are recorded from the time of sensor placement until discharge from hospital and assessed for causal relationship to the investigational device by the investigator. Anticipated device-related events include topical bleeding at the sensor attachment site, local tissue reaction associated with tissue glue fixation, and local infection at the insertion site.

Time frame
From sensor placement during the operation until discharge from hospital (up to 30 days)

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Spectrocor

Lead sponsor

Helsinki University Central Hospital

Collaborator

This trial is not recruiting at the moment. You can still explore other options: